Durability of Humoral Responses after the Second Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility

Abstract

Residents of long-term care facilities (LTCFs) have been dramatically hit by the COVID-19 pandemic on a global scale as older age and comorbidities pose an increased risk of severe disease and death. The aim of the study was to assess the quantity and durability of specific antibody responses to SARS-CoV-2 after the first cycle (two doses) of BNT162b2 vaccine. To achieve this, SARS-CoV-2 Spike-specific IgG (S-IgG) titers was evaluated in 432 residents of the largest Italian LTCF at months 2 and 6 after vaccination. By stratifying levels of humoral responses as high, medium, low and null, we did not find any difference when comparing the two time points; however, the median levels of antibodies halved overtime. As positive nucleocapsid serology was associated with a reduced risk of a suboptimal response at both time points, we conducted separate analyses accordingly. In subjects with positive serology, the median level of anti-S IgG slightly increased at the second time point, while a significant reduction was observed in patients without previous exposure to the virus. At month 6, diabetes alone was associated with an increased risk of impaired response. Our data provide additional insights into the longitudinal dynamics of the immune response to BNT162b2 vaccination in the elderly, highlighting the need for SARS-CoV-2 antibody monitoring following third-dose administration.

Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study

“…The correlation of both IgG and neutralising antibody concentrations with disease intensity shows that even if antibody concentrations are not high enough to protect from infection, they can reduce the severity of disease. Overall, the results of this study, together with the shown waning of humoral response following the second vaccine dose, 6 , 17 highlight the importance of high antibody concentrations for protection against SARS-CoV-2 infection. Booster doses—which have been shown to be effective for increasing antibody concentrations, 18 , 19 —are currently the most important course of action for increased protection against infection.…”

Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study

“…The currently approved and available vaccines have different mechanisms of action in triggering the immune system to produce immune response biomarkers that predict vaccine effectiveness. Several studies have discussed the vaccine effect of various vaccine types on inducing immune responses to produce immune biomarkers and their durability (4)(5)(6)(7)(8). However, these studies were limited in examining the effect of whole inactivated vaccine, the effect of vaccine mixing between more than one type, and the change in immunity levels by the number and type of the received vaccine doses on different forms of immunity.…”

An epidemiological survey of COVID-19 serology and its association with clinical infection among older adults – Does antibody titer matter?

“…This nding is supported by previous reports (7-9). Lai et al showed a decrease in the median antibody titer between 2 and 6 months after the second COVID19 vaccination (7). This has also been reported post infection (10).…”